



Pharmawand User Guide

Pharmawand has been created for publishers and agencies who are involved in the provision of marketing advice, marketing services and medical education for the pharmaceutical industry. It is essentially a market intelligence site.

Pharmawand can be described as a drug dataset that comprises drugs from phase II to market providing constantly renewed information on all aspects of drug development and marketing, including important clinical trial information, registration status, sales data and marketing allocations, mechanisms of drugs, investigators of leading trials, selected citations and commentaries. The site is accompanied by a daily news service that can post immediate news to the email addresses of its users.

Pharmawand contains 5 tabs: **Home, Search, Feedback, News and My Profile**. The **Search** tab is the default tab when a user enters the site.

Search

The search tab is the starting point from where the user can search the Pharmawand database to find the drugs that are of interest to the user. The fields that are currently searchable are highlighted below in diagram 1.1. Any combination of fields are searchable together and a logical AND is applied between multiple selections.

For example if the user selects Condition=ADHD and Developer=Shire, the results panel will display all drugs for ADHD that are developed by Shire.

Some companies have groups comprising several entities, for example Shire and Shire Regenerative Medicine or Abbott Labs, AbbVie, Abbott Vascular and Abbott Molecular. Care should be taken to select the correct company for your purpose.

The screenshot shows the Pharmawand website's search interface. The header includes the Pharmawand logo and navigation links. The search panel contains several filter categories, each with a list of options and a 'Clear' link. A 'Search' button is located at the top right of the panel. Red circles highlight specific fields and options across the interface.

Searchable Fields (Circled in Red):

- Therapies:** Aesthetic Therapy, Anaesthesia, Cardiology, Cardiovascular, Cerebrovascular, Critical Care, Dermatology, Diabetes, Endocrinology, Gastroenterology.
- Condition:** Abdominal Aortic Aneurysm, ACE Inhibitor induced Angioec, Achondroplasia, Acne, Acromegaly, Actinic Keratosis, Acute Coronary Syndrome, Acute Kidney Injury, Acute Limb Ischemia, Acute Liver Failure.
- Developer:** (Empty text field)
- Marketing Company:** (Empty text field)
- Orphan:** ☐
- Trade Name:** (Empty text field)
- Generic Name:** (Empty text field)
- Keyword Search:** (Empty text field)
- Approval Status:** 510(k) Approval, Accelerated Approval, Advisory Committee Negative, Advisory Committee Recomm, Approvable, Approved, Approved Conditionally, Cancelled, Cancelled/Withdrawn, CE MARK Approved.
- Status Region:** Africa, All, APAC, ASEAN, Asia, BeNeLux, Central America, CIS, Eastern Europe, EU.
- Status Country:** Afghanistan, Albania, Algeria, American Samoa, Andorra, Angola, Anguilla, Antigua and Barbuda, Argentina, Armenia.
- Nice:** (Dropdown menu)
- BioSimilar:** ☐
- Last Update Date:** (Calendar icon and empty text field)
- Block Buster Status:** CBB, PBB.

View Results by:

- ☒ Details
- ☐ Financials
- ☐ Block Buster

Diagram 1.1 - Searchable fields

The user makes their selection and then clicks the Search button. At which point the search criteria panel is hidden and the results panel is displayed, if matching results have been found, as highlighted below in diagram 1.2. A detailed description of the search panel can be found in the next section.

pharmawand PHARMACEUTICALS • MEDICAL DEVICES • NUTRITIONALS							
Trends	Search	Product News	Company News	My Account	Help	Guest	[Sign Out]
New Search		Download To Excel					
Trade Name	Generic Name	Condition	Marketing Company and Region	Drug Status	Update Date		
View Drug Details	canagliflozin+metformin	Diabetes Type 2	Janssen Pharmaceuticals Inc-Africa Janssen Pharmaceuticals Inc-EU Janssen Pharmaceuticals Inc-Latin America Janssen Pharmaceuticals Inc-Middle East Janssen Pharmaceuticals Inc-North America Mitsubishi Tanabe-ROW	Complete Response USA 16/12/2013	16/12/2013		
View Drug Details	mesenchymal precursor cells	Diabetes Type 2	Mesoblast Ltd-All	Phase II USA 07/12/2013	07/12/2013		
View Drug Details	D-Tagatose	Diabetes Type 2	Spherix Inc.-All	Phase III USA	04/06/2011		
View Drug Details	balaglitazone	Diabetes Type 2	Dr Reddy-ROW Nordic Pharma-China Nordic Pharma-EU	Phase III USA	09/05/2012		
View Drug Details	tasoglutide	Diabetes Type 2	Ipsen-ROW Teijin-Japan	Pivotal Trial Failed USA	02/08/2013		
View Drug Details	dapagliflozin	Diabetes Type 1	AstraZeneca-All BMS-All	Phase II USA 23/06/2013	04/08/2013		
View Drug Details	ladarixin	Diabetes Type 1	Dompe-All	Phase II EU	27/02/2012		
View Drug Details	tenilzumab	Diabetes Type 1	MacroGenics-All	Phase II USA 07/08/2013	23/08/2013		

Diagram 1.2 - Results Panel

Multiple selections of Therapies and Condition list boxes are possible by holding the Shift or Ctrl keys while selecting the required Therapies or Conditions. In diagram 1.3 two Therapies and three Conditions have been selected.



Trends **Search** Product News Company News My Account Help Guest [Sign Out]

Enter a saved search name

Therapies Aesthetic Therapy Anaesthesia Cardiology Cardiovascular Cerebrovascular Critical Care Dermatology Diabetes Endocrinology Gastroenterology Clear	Condition ACE Inhibitor induced Angioec Amyloidosis Atherosclerosis Athrothrombosis Buerger's Disease, Cardiac Stents Cardiovascular Risk Carotid Artery Disease Cerebral Aneurysm Chronic Myocardial Ischaemia Clear	Developer Marketing Company Orphan ☐	Trade Name Generic Name Keyword Search
Approval Status 510(k) Approval Accelerated Approval Advisory Committee Negative Advisory Committee Recomm Approvable Approved Approved Conditionally Cancelled Cancelled/Withdrawn CE MARK Approved Clear	Status Region Africa All APAC ASEAN Asia BeNeLux Central America CIS Eastern Europe EU Clear	Status Country Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Clear	Nice BioSimilar ☐ Last Update Date

Diagram 1.2 - Multiple selections of Therapies and Condition

The fields Developer, Marketing Company, Trade Name and Generic Name have the type-ahead feature enabled. If the corresponding value is not displayed in the type-ahead list a match has not been found in the database therefore the user should amend their search.

The saved search functionality allows the user to save search criteria for re-use at a later date. To access this functionality, on the search page, next to the Search button, there is a text box to enter the name of your search (which is optional). Select the search criteria and search as normal. The next time you come back to the search page, you will notice a drop down list next to the Search button. Select one of your previously saved searches and the criteria will be re-populated on the search form. To delete previously saved searches, please go to the My Profile page.



Trends **Search** Product News Company News My Account Help Guest [Sign Out]

Enter a saved search name

Therapies Condition Developer Trade Name

Searchable Field Description

Therapies

Therapies group one or more conditions together. A search by a Therapy or Therapies searches all the drugs that are linked to the related conditions. For example Therapy Critical Care contains the follow Conditions: Bronchopulmonary Dysplasia, Distributive Shock Critical Care, Multiple Organ Dysfunction Syndrome, Shock, and Septic Shock. So if the user just selects this Therapy, then the search results panel will display all drugs that are in these Conditions.

Conditions

A search by **Condition** or Conditions directly searches all drugs that match the user's selection. A Condition is akin to the indication of the drug

Drug Searches

If the user knows the **Trade Name** or **Generic Name** of the drug they can search directly using either of these two fields. These fields support the type-ahead functionality.

Company searches

The user can search by the **Marketing Company** and this will return all drugs marketed by this company. The user can search by the **Developer** and this will return all drugs developed by this company. These fields support the type-ahead functionality.

Approval Status Search

The user can search for drugs by **Approval Status** by selecting one or multiple (hold down shift or Ctrl keys and select) approval statuses from the list box. A drug's **Approval Status** classifies where it is in the development and approval process.

For example select **Condition**= Diabetes Types 1&2 and **Approval Status**= CHMP Recommended and the results will list all drugs for that condition that CHMP Recommended. Another example would be **Marketing Company** = Merck Inc. and **Approval Status** = Complete Response and the results will list all drugs for Merck Inc. that are FDA Complete Response.

Status Region

The user can further refine their search by **Status Region** by selecting one or multiple (hold down shift or Ctrl keys and select) status regions from the list box. The status region is the region of the corresponding Approval Status.

For example the user can search for all drugs that are **Approval Status**= CHMP Recommended, in the EU.

Status Country

The user can further refine their search by **Status Country** by selecting one or multiple (hold down shift or Ctrl keys and select) status countries from the list box.

For example the user can search for all drugs that are **Approval Status**= Early Study, in France.

NICE (applies to UK)

The user can search for drugs by **NICE** status by selecting one of the **NICE** statuses from the dropdown list.

For example the user could search for **NICE** = Approved and **Marketing Company** = Novartis, this will return all the drugs with NICE approval for Novartis that are in the database.

Search by Last Update

The user can search by the date that the drug was last updated by the Pharmawand editorial team. The date is updated whenever the editorial team edit any field either to add additional information. The user can click on the calendar icon and select the desired date or they can type the date in manually, which should be in the UK date format (dd/mm/yyyy).

For example the user could select Condition = Diabetes Type 2 and the 01/07/2012, which will return all drugs that are for condition Diabetes Type 2 that had been edited on or after the 1st July 2012.

If the **Last Update Date** field is used in conjunction with **Approval Status**, additional logic is applied such that the **Last Update Date** applies to when the drug changed to the approval status that matches the user's selection. For example if the user selected **Approval Status**=CHMP Recommended and **Last Update Date**= 01/10/2012, this will return all drugs that have had their **Approval Status** changed to CHMP Recommended on or after the 01/10/2012.

Keyword Search

The **Keyword Search** box allows the user to search for one or more words across the whole Pharmawand database. The search will match the exact words enter therefore search for "McMaster University" will only return drugs that have those words in that sequence. In this example it will not bring back any drug with "McMaster" or "University". If this is what the user wants to search for they will have to execute two separate searches one for "McMaster" and another for "University".

BioSimilar

Checking this checkbox constrains by BioSimilar drugs.

Block Buster Status

Select CBB for confirmed Block Buster drugs. Select PBB for potential Block Buster drugs.

Search Results Panel Functionality

The user can currently view their results by three different views which can be selected at the end of the search criteria panel.



Details displays the following information



PHARMACEUTICALS • MEDICAL DEVICES • NUTRITIONALS



Trends Search Product News Company News My Account Help Guest [Sign Out]

New Search Download To Excel

Trade Name	Generic Name	Condition	Marketing Company and Region	Drug Status	Update Date
View Drug Details	tasoglutide	Diabetes Type 2	Ipsen-ROW Teijin-Japan	Pivotal Trial Failed USA	02/08/2013

Financials displays the following information



PHARMACEUTICALS • MEDICAL DEVICES • NUTRITIONALS



Trends Search Product News Company News My Account Help Guest [Sign Out]

New Search Download To Excel

Trade Name	Generic Name	Financial Prediction	Sales	Update Date
CSG 452	tofogliflozin			06/03/2014
CTP 499				19/05/2014
Cycloset	bromocriptine mesylate		2014 Q1 \$ 10.1 2014- Q1 sales at Salix \$ 10.1 m.	19/09/2014
Cymbalta	duloxetine	July 2013-Cymbalta earned in 2012 around \$5 billion, \$4 billion in the U.S., but it will lose patent protection at the end of 2013. It was expected to go off patent June 30. but Lilly in 2012 won a 6-month	2014 Q1 \$ 1328.0 First quarter sales 2014 at Eli Lilly were \$478.2 million compared to \$1.328 billion for first quarter 2013. Down 64%. Down 64%.	08/12/2014

BlockBuster displays the following information



PHARMACEUTICALS • MEDICAL DEVICES • NUTRITIONALS



Trends Search Product News Company News My Account Help Guest [Sign Out]

New Search Download To Excel

Trade Name	Marketing Company and Region	Status	Sales	Patent Expiry
Abilify	BMS-All	CBB	2013 \$ 2,289 Bn	2014

If the user's search criteria have matched one or more drugs in the database the results are displayed in the search results panel, as seen in diagram 2.1.



Trends	Search	Product News	Company News	My Account	Help	Guest	[Sign Out]
New Search		Download To Excel					
Trade Name	Generic Name	Condition	Marketing Company and Region	Drug Status	Update Date		
View Drug Details	canagliflozin+metformin	Diabetes Type 2	Janssen Pharmaceuticals Inc-Africa Janssen Pharmaceuticals Inc-EU Janssen Pharmaceuticals Inc-Latin America Janssen Pharmaceuticals Inc-Middle East Janssen Pharmaceuticals Inc-North America Mitsubishi Tanabe-ROW	Complete Response USA 16/12/2013	16/12/2013	☐	
View Drug Details	mesenchymal precursor cells	Diabetes Type 2	Mesoblast Ltd-All	Phase II USA 07/12/2013	07/12/2013	☐	
View Drug Details	D-Tagatose	Diabetes Type 2	Spherix Inc.-All	Phase III USA	04/06/2011	☐	
View Drug Details	balaglitazone	Diabetes Type 2	Dr Reddy-ROW Nordic Pharma-China Nordic Pharma-EU	Phase III USA	09/05/2012	☐	
View Drug Details	taspoglutide	Diabetes Type 2	Ipsen-ROW Teijin-Japan	Pivotal Trial Failed USA	02/08/2013	☐	
View Drug Details	dapagliflozin	Diabetes Type 1	AstraZeneca-All BMS-All	Phase II USA 23/06/2013	04/08/2013	☐	
View Drug Details	ladarixin	Diabetes Type 1	Dompe-All	Phase II EU	27/02/2012	☐	
View Drug Details	tenilzumab	Diabetes Type 1	MacroGenics-All	Phase II USA 07/08/2013	23/08/2013	☐	

Diagram 2.1 Search Results Panel

The search results panel displays a grid with one row per drug and columns for the key drug fields: Trade Name, generic Name, Condition, Marketing Company and Region, Drug Status, Update Date. There is also a column to select the drug of Excel Download, which is described in more detail later on.

The Trade Name field is hyperlinked to the Drug Details page where all the drug information can be found. If the drug has no trade name the text “View Drug Details” appears in the Trade Name field.

Pagination

If the search criterion matches more than 25 drugs the pagination bar is displayed and can be found at the bottom of the search results panel.

1	2	3	4	5	6	7	8
---	---	---	---	---	---	---	---

Page 1 of 8

The maximum number of results that a user’s search can return is 250 drugs. If this occurs and the user can’t find what they are looking for, it is recommended that the user refines their search criteria and searches again to find the drugs that they are interested in.

Sorting

By default the results are sorted by the field Trade Name in ascending alphabetical order. Each of the columns is sortable by clicking on the column heading. If the user clicks the same heading more

than once in succession the sort order with toggle between ascending and descending. Drugs that have not yet been given a trade name appear in the results grid with a name “[View Drug Details](#)” and are displayed at the top of the list and then the drugs with trade names alphabetically.

Transfers to Excel

The drugs returned by a user’s search can be downloaded to Excel by selecting the checkbox next to each drug and clicking on the button **Download To Excel**. This functionality can assist users in creating internal briefing notes. The resulting download will contain all the information held in the database for the selected drugs. The user can select all the drugs on one results page by selecting the checkbox in the header bar, as highlighted below. This checkbox will toggle on and off the checkboxes for all the drugs on one results page. If the user wishes to download multiple pages of results to Excel they must do it a page at a time.



Drug Details

The drug details page displays all the information held in the database for the selected drug. This page can be reached from the search results grid or the Product News results.

pharmawand
PHARMACEUTICALS • MEDICAL DEVICES • NUTRITIONALS



TrendsSearchProduct NewsCompany NewsMy AccountHelpGuest[Sign Out]

Drug DetailsFeedback on this Drug<< Back to Search Results

Generic Name	alteplase	Trade Name	Actilyse/Cathflo
Condition	Acute Myocardial Infarction	Other Trade Names	activase - EU
Marketing Company	Boehringer - EU Genentech/Roche - USA	Developer	Genentech/Roche

Registration Status
EU approved FDA 1996;FDA approved 18 June 1996. NICE recommended 2002. UK approved 29 November 2011.

Class tPA

Mechanism A serine protease (EC 3.4.21.68) found on endothelial cells, the cells that line the blood vessels. As an enzyme, it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. Because it works on the clotting system, tPA is used in clinical medicine to treat only embolic or thrombolytic stroke. Use is contraindicated in hemorrhagic stroke and head trauma. Alteplase is a tissue plasminogen activator produced by recombinant DNA technology. The most common complication encountered during alteplase, recombinant therapy is bleeding.

Last Updated 03/02/2014

Useful Citation Main interest is for stroke as Metalyse (tenecteplase) has succeeded to the market in MI.

The Last Updated field is the most recent date that any edit to the drug was made. The Other Conditions field displays the other conditions that also list this drug in the generic name field.

News

When the user clicks on the News tab the user is by default shown the **Latest Product News**. The user can click on **Pharma Company News** sub tab to see news items relating to Pharma companies rather than individual product news.

For each news items the Product News provides the following information.

Headline Date

Headline - Hyperlinked to the drug details page.

New Article

Marketing Company, Drug Trade name, Drug Generic Name, Condition

The screenshot displays the Pharmawand website's 'Latest Product News' section. The header features the 'pharmawand' logo with the tagline 'PHARMACEUTICALS • MEDICAL DEVICES • NUTRITIONALS' and a navigation bar with links: Trends, Search, Product News (highlighted), Company News, My Account, Help, Guest, and [Sign Out]. A search bar with a 'Search Archive' button is also present. The main content area shows a news article dated '10/02/2014'. The headline is 'FDA issues Complete Response Letter for RB 103 for Migraine-RedHill BioPharma'. The article text describes a Complete Response Letter (CRL) from the FDA regarding a New Drug Application (NDA) for RHB-103, a proprietary oral thin film formulation of rizatriptan benzoate. It mentions that the questions raised by the FDA relate to third-party Chemistry, Manufacturing and Controls, and packaging, while the product's safety and the FDA's CRL do not require additional clinical studies. The article concludes with the statement: 'While continuing to review the FDA's CRL, RedHill and IntelGenx believe that they can supply the requested information based on available data.' At the bottom, the article is attributed to 'IntelGenx Corp.-All' and 'Red Hill Biopharma-All, RHB 103, film formulation of rizatriptan, Migraine/Headache'. Red annotations with arrows point to the date, headline, article text, and the attribution line.

10/02/2014

FDA issues Complete Response Letter for RB 103 for Migraine-RedHill BioPharma

RedHill Biopharma Ltd. an Israeli biopharmaceutical company together with IntelGenx Corp., a Canadian drug delivery company have announced that they received a Complete Response Letter (CRL) from the FDA regarding the New Drug Application (NDA) for RHB-103 for the treatment of acute Migraines. RHB-103 is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT₁ receptor agonist and the active drug in Merck & Co.'s Maxalt.

The questions raised by the FDA in the CRL regarding the NDA for RHB-103 primarily relate to third party Chemistry, Manufacturing and Controls and to the packaging and labeling of the product. No questions or deficiencies were raised relating to the product's safety and the FDA's CRL does not require additional clinical studies. While continuing to review the FDA's CRL, RedHill and IntelGenx believe that they can supply the requested information based on available data.

IntelGenx Corp.-All
Red Hill Biopharma-All, RHB 103, film formulation of rizatriptan, Migraine/Headache

10/02/2014

The news items are ordered date descending (newest first) and the last 3 months of news is selected split by 25 news items per page.

The user can free text search all news in the database by entering text into the search box and clicking on the **Search News Archive** button. If the user does enter some search text they is no date filter applied and all the news archive is searched. The user can remove the search filter by clicking on the **News** tab again or by removing the search text and clicking on the **Search News Archive** button.

For example the user could enter "VEGF" and click the **Search News Archive** button. At the time of writing this guide this search returns 16 new items.

The screenshot shows the 'Latest Product News' section of the Pharmawand website. It features a search bar with a 'Search Archive' button next to it.

Latest Product News

Search Archive

At the bottom of the page the user can paginate through the selected news items, if there are more than 25 items returned by the search.

[Previous](#) [Next](#)
Page: 1 of 11

My Account

The **My Account** tab contains three main sections, the first detailing the user's details, the second section listing the user's news alerts and the third the list of saved searches.

The user can update their details and if they want to change their password they can click the down arrows to expand this section. Once any edits have been made the user should click the **Save My Profile** button to save any changes.

pharmawand
PHARMACEUTICALS • MEDICAL DEVICES • NUTRITIONALS

Trends Search Product News Company News **My Account** Help Guest [Sign Out]

My Profile

Save My Profile

First Name
Guest

Last Name
Welcome

Email
guest@pharmawand.co.uk

Old Password
New Password
Repeat Password

My Alerts

New Alert

Alert Name	Alert Frequency	Status	Recent Matches
Diabetic foot	Weekly	Active	Click Here
mucositis	Daily	Active	Click Here
acne	Daily	Active	Click Here
liver failure	Daily	Active	Click Here

My Saved Searches

Action	Saved Search Name
Delete	test1

Alerts in Pharmawand are the mechanism by which news items are emailed to users.

The **My Alerts** section is made up of the **New Alert** button and the alert summary grid. If the user doesn't have any alerts currently set up only the **New Alert** button is displayed. The alert summary grid displays four columns: Alert Name, Alert Frequency, Status and Recent Matches. The **Alert**

Name column is hyperlinked to the **Edit Alert** page. The **Recent Matches** column is hyperlinked to the news page and displays the 50 most recent news items that have matched the alert.

The **My Saved Searches** section allows the user to delete saved searches that were created on the search page.

Edit Alert

The **Edit Alert** page allows the user to set up and edit their alert profiles. The Edit Alert page is split into two sections; the top section has the following fields: **Alert Name** and **Frequency**. The **Alert Name** field takes any text string up to 45 characters and represents the logical name the user chooses to identify this alert profile by. The **Frequency** list box has three values that represent when the alert email is sent: Daily, Weekly and Monthly. If for example the user has selected Daily, any news items that match their criteria in the last 24 hours will be emailed to the user, likewise for weekly and monthly.

The **Alert Criteria** section allows the user to select criteria that will match against drugs that have news in the period specified by the **Frequency** field. This section functions in a similar way to the Search tab. Once the user has made their selection, they should click the **Save Alert Profile** button to save their changes. If the user no longer wishes to receive the news emails they can delete their profile by clicking on the **Delete Alert Profile** button.

For example if the user doesn't enter any criteria, this alert profile will match all news items in the specified period. If the user selects **Condition**=Acute Liver Failure, they will be emailed any news stories that are for drugs where the condition is Acute Liver Failure. If the user selects **Developer**=AstraZeneca, the user will be emailed Product news for Astra Zeneca's drugs and Company news about AstraZeneca.

The screenshot shows the 'Edit Alert' page on the Pharmawand website. The header is blue with the 'pharmawand' logo and the text 'PHARMACEUTICALS • MEDICAL DEVICES • NUTRITIONALS'. Navigation links include 'Trends', 'Search', 'Product News', 'Company News', 'My Account' (highlighted), and 'Help'. User status is 'Guest' with a '[Sign Out]' link.

The 'Edit Alert' section has three buttons: 'Cancel Edit', 'Delete Alert', and 'Save Alert'. Below these are two main input areas:

- Alert Name:** A text box containing 'Diabetic foot'.
- Frequency:** A dropdown menu set to 'Weekly'.

The 'Alert Criteria' section contains three columns of selection options:

- Therapies:** A list box with options: Aesthetic Therapy, Anaesthesia, Cardiology, Cardiovascular, Cerebrovascular, Critical Care, Dermatology, Diabetes, Endocrinology, Gastroenterology, and Clear.
- Condition:** A list box with options: Depression, Dermal Filler, Dermatitis, Diabetes and Dyslipidaemia, Diabetes Type 1, Diabetes Type 2, Diabetes Type 2 and Kidney, Diabetes Types 1 & 2, Diabetes/Hepatic Disorders, and Diabetic Foot (highlighted).
- Developer:** A text box.

Below these are three more text boxes: **Trade Name**, **Generic Name**, and **Other Names**.

At the bottom, there is a 'Marketing Company' text box and a footer with links: 'Top | Home | Terms | Contact Us | Feedback | © 2014 PharmaWand LLP'.

Alert Emails

When an alert profile's criterion matches Product or Company news items the user will be sent an email. An example of the resulting email from a news item matching against an alert profile is shown below. The alert name as specified on the Edit Alert page is displayed in the email, for example the alert name in the email below is "Catch All Daily Alert". This alert profile has matched against four news items and displays their headlines in the alert email. The user can individually click on each news headline to see the details in the Pharmawand site or they can click on the "**click here**" hyperlink to read all the news stories on one page.

Dear Andy,

Here are the latest Catch All Daily Alert news alerts:

[EU approves Votubia \(Novartis\) for Renal Angiomyolipoma](#)
[FDA Advisory Committee recommends raxibacumab \(HGS\), for Anthrax](#)
[GALNS \(BioMarin\) success in Phase III study for MPS IVA](#)
[Epanova \(Omthera Pharma\) successes in EVOLVE and ESPIRIT trials for Dyslipidaemia](#)

To read all the news listed in this email alert [click here](#)

Best wishes

Pharmawand

Feedback

The feedback tab allows the user to quickly submit any feedback they may have to the Pharmawand editorial team.

pharmawand
PHARMACEUTICALS • MEDICAL DEVICES • NUTRITIONALS



TrendsSearchProduct NewsCompany NewsMy AccountAdminHelpAndy[Sign Out]

Please send us your feedback

Submit

First Name

Guest

Last Name

House

Email

thehouse

Comment

Great site

[Top](#) | [Home](#) | [Contact](#) | [Terms](#) | [Contact Us](#) | [Feedback](#) | © 2014 PharmaWand LLP

Glossary

The glossary is intended to help identify acronyms of medical conditions referred to in the Conditions search list box.

PharmaWand Glossary and Definitions

This glossary is intended to help identify acronyms of medical conditions referred to in the Conditions search.

Conditions

BRVO BRVO Branch Retinal Vein Occlusion is a blockade that occurs in one of the branching retinal veins that drain blood from the retina. The blockage can lead to Macular Oedema.

CAPS Cryopyrin Associated Periodic Syndrome is a spectrum of auto-inflammatory syndromes including Familial Cold Auto-inflammatory Syndrome and Muckle Wells Syndrome and NOMID which is Neo Natal Onset Multisystem Inflammatory Disease.

CIDP Chronic Inflammatory Demyelinating Polyneuropathy, an acquired immune mediated inflammatory disorder of the peripheral nervous system.

CMV Cytomegalovirus, a viral genus of the family of herpes viruses.

CRVO Central Retinal Vein Occlusion, a cessation of the blood supply via the central retinal artery and vein to the retina.


CTEPH Chronic Thromboembolic Pulmonary Hypertension, a type of Pulmonary Hypertension occurring in the arteries that carry blood to the lungs.

F XIII Congenital Factor XIII Deficiency is a rare blood disorder.

GERD (US)/GORD (EU) Gastro-oesophageal Reflux Disease, a chronic symptom of mucosal damage caused by stomach acid from the stomach to the oesophagus.

Remember Me

On the public home page just below where the user enters their email and password there is a checkbox called **“Remember Me at this computer”**.



Sign In

Email

Password

[Forgot your password?](#)

Remember Me at this computer: ☐

Sign In

If the user checks this checkbox and successfully enters the site, a cookie will be set on their computer, for the current browser, containing the user’s email and password. The next time the user comes to access the site, the login page will be skipped and the user signed-in automatically. Clicking the logout button clears this cookie.

Do not use this functionality on shared or public computers.